|Mr. Joseph C. Papa||CEO & Chairman||10.72M||N/A||1955|
|Mr. Paul S. Herendeen||Exec. VP & CFO||10.75M||N/A||1956|
|Ms. Christina M. Ackermann||Exec. VP & Gen. Counsel||2.04M||N/A||1965|
|Mr. J. Michael Pearson||Former Chief Exec. Officer||11.97M||60.51M||1959|
|Mr. Osama A. Eldessouky||Sr. VP, Controller & Chief Accounting Officer||N/A||N/A||1972|
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Valeant Pharmaceuticals International, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 4; Compensation: 10.